All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 CD20 (2F2) h(ICOSBBζ), which is constructed for the engineering of T cells to target human CD20. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-CD20 antibody linked to ICOS (CD278) signaling domain and CD137 (4-1BB), CD3-zeta signaling domains. And the vector product was designed for the treatment of Acute lymphoblastic leukemia (ALL).
CAR Construction : Fig.1 Antigen binding activity of anti-CD20. Raji cells were incubated with differentconcentrations of C2B8-FITC, 2F2-FITC, C2B8(ScFvHL)4-Fc-FITC, or 2F2(ScFvHL)4-Fc-FITC for 1 h at 4°C. Then, the cells were washed and analyzed by FCM. Li, B., Shi, S., Qian, W., Zhao, L., Zhang, D., Hou, S., ... & Guo, Y. (2008). Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer research, 68(7), 2400-2408. |
CAR Construction : Fig.2 Competitive binding assay. Binding of C2B8-FITC (Left ) or 2F2-FITC (Right ) to Raji cells in the presence of increasing concentrations of competitor antibodies. Li, B., Shi, S., Qian, W., Zhao, L., Zhang, D., Hou, S., ... & Guo, Y. (2008). Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer research, 68(7), 2400-2408. |
CAR Construction : Fig.3 The binding properties of anti-CD20. Dissociation of anti-CD20 mAbs fromRaji cells. Cells were incubated with 10 μg/mL of 11B8-FITC, 2F2-FITC,2F2(ScFvHL)4-Fc-FITC, or 11B8/2F2(ScFvHL)4-Fc-FITC at 37°C for 45min, washed twice, and resuspended in complete medium. Li, B., Zhang, X., Shi, S., Zhao, L., Zhang, D., Qian, W., ... & Guo, Y. (2010). Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. Cancer research, 70(15), 6293-6302. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD20 (2F2) h(ICOS-4-1BB-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX490). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION